Abiopharma

Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases

NASDAQ traded attribute type Security_Name was changed. Previous value: Kronos Bio, Inc. - Common Stock. New value: Kronos Bio, Inc. - Common Stock.

NASDAQ traded attribute type Test_mode was changed. Previous value: N. New value: Kronos Bio, Inc. - Common Stock.

NASDAQ traded attribute type Financial_Status was changed. Previous value: N. New value: Kronos Bio, Inc. - Common Stock.

Cordlife To Hold Townhalls For affected Clients In Singapore; Explores Improvements To Proposal For Affected Customers

Townhall Meetings to be held from 23 June 2025 to 25 June 2025 and Press Release

General Announcement: Townhall Meetings to be held from 23 June 2025 to 25 June 2025 and Press Release

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025

Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress

Lillys once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

QIPT Investors Have Opportunity to Join Quipt Home Medical Corp. Fraud Investigation with the Schall Law Firm

RCKT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

General Announcement: Refund Of Excess Claim of Cost Of Material For FY2024

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG